These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
161 related articles for article (PubMed ID: 38739094)
1. A predictive nomogram for short-term outcomes of myasthenia gravis patients treated with low-dose rituximab. Zhou Y; Guo R; Xia X; Jing S; Lu J; Ruan Z; Luo S; Huan X; Zhao C; Chang T; Xi J CNS Neurosci Ther; 2024 May; 30(5):e14761. PubMed ID: 38739094 [TBL] [Abstract][Full Text] [Related]
2. Nomogram for short-term outcome assessment in AChR subtype generalized myasthenia gravis. Zhao R; Wang Y; Huan X; Zhong H; Zhou Z; Xi J; Da Y; Lei L; Chang T; Ruan Z; Luo L; Li S; Yang H; Li Y; Luo S; Zhao C J Transl Med; 2021 Jun; 19(1):285. PubMed ID: 34193193 [TBL] [Abstract][Full Text] [Related]
3. Comparison Between Rituximab Treatment for New-Onset Generalized Myasthenia Gravis and Refractory Generalized Myasthenia Gravis. Brauner S; Eriksson-Dufva A; Hietala MA; Frisell T; Press R; Piehl F JAMA Neurol; 2020 Aug; 77(8):974-981. PubMed ID: 32364568 [TBL] [Abstract][Full Text] [Related]
4. Short-term effect of low-dose rituximab on myasthenia gravis with muscle-specific tyrosine kinase antibody. Zhou Y; Yan C; Gu X; Zhou L; Lu J; Zhu W; Huan X; Luo S; Zhong H; Lin J; Lu J; Zhao C; Xi J Muscle Nerve; 2021 Jun; 63(6):824-830. PubMed ID: 33745138 [TBL] [Abstract][Full Text] [Related]
5. Low-dose rituximab every 6 months for the treatment of acetylcholine receptor-positive refractory generalized myasthenia gravis. Lu J; Zhong H; Jing S; Wang L; Xi J; Lu J; Zhou L; Zhao C Muscle Nerve; 2020 Mar; 61(3):311-315. PubMed ID: 31875994 [TBL] [Abstract][Full Text] [Related]
6. Long-term follow-up of patients with myasthenia gravis treated with low-dose rituximab. Chan F; Swayne A; Gillis D; Walsh M; Henderson RD; McCombe PA; Wong RC; Blum S J Neurol Neurosurg Psychiatry; 2019 Aug; 90(8):955-956. PubMed ID: 30455407 [No Abstract] [Full Text] [Related]
7. Refractory myasthenia gravis - clinical profile, comorbidities and response to rituximab. Sudulagunta SR; Sepehrar M; Sodalagunta MB; Settikere Nataraju A; Bangalore Raja SK; Sathyanarayana D; Gummadi S; Burra HK Ger Med Sci; 2016; 14():Doc12. PubMed ID: 27790079 [No Abstract] [Full Text] [Related]
8. Resistant myasthenia gravis and rituximab: A monocentric retrospective study of 28 patients. Afanasiev V; Demeret S; Bolgert F; Eymard B; Laforêt P; Benveniste O Neuromuscul Disord; 2017 Mar; 27(3):251-258. PubMed ID: 28082209 [TBL] [Abstract][Full Text] [Related]
9. Rituximab as induction therapy in refractory myasthenia gravis: 18 month follow-up study. Singh N; Goyal V J Neurol; 2019 Jul; 266(7):1596-1600. PubMed ID: 30919039 [TBL] [Abstract][Full Text] [Related]
10. Rituximab as Adjunct Maintenance Therapy for Refractory Juvenile Myasthenia Gravis. Zingariello CD; Elder ME; Kang PB Pediatr Neurol; 2020 Oct; 111():40-43. PubMed ID: 32951658 [TBL] [Abstract][Full Text] [Related]
11. High efficacy of rituximab for myasthenia gravis: a comprehensive nationwide study in Austria. Topakian R; Zimprich F; Iglseder S; Embacher N; Guger M; Stieglbauer K; Langenscheidt D; Rath J; Quasthoff S; Simschitz P; Wanschitz J; Windisch D; Müller P; Oel D; Schustereder G; Einsiedler S; Eggers C; Löscher W J Neurol; 2019 Mar; 266(3):699-706. PubMed ID: 30649616 [TBL] [Abstract][Full Text] [Related]
12. Low-dose rituximab treatment for new-onset generalized myasthenia gravis. Li H; Huang Z; Jia D; Xue H; Pan J; Zhang M; Shi K; Shi FD; Zhang C J Neuroimmunol; 2021 May; 354():577528. PubMed ID: 33662696 [TBL] [Abstract][Full Text] [Related]
13. Promising efficacy of Low-Dose rituximab in Muscle specific kinase antibody positive Myasthenia Gravis. Yang X; Zhang W; Chang X; Li Z; Du R; Guo J Neurosci Lett; 2024 Jan; 818():137561. PubMed ID: 37984485 [TBL] [Abstract][Full Text] [Related]
17. Rituximab as a sole steroid-sparing agent in generalized myasthenia gravis: Long-term outcomes. Kefalopoulou ZM; Veltsista D; Germeni A; Lykouras D; Tsiamaki E; Chroni E Neurol Sci; 2024 Mar; 45(3):1233-1242. PubMed ID: 37831214 [TBL] [Abstract][Full Text] [Related]
18. Development and validation of a risk nomogram for postoperative acute kidney injury in older patients undergoing liver resection: a pilot study. Yu Y; Zhang C; Zhang F; Liu C; Li H; Lou J; Xu Z; Liu Y; Cao J; Mi W BMC Anesthesiol; 2022 Jan; 22(1):22. PubMed ID: 35026992 [TBL] [Abstract][Full Text] [Related]
19. Use and monitoring of low dose rituximab in myasthenia gravis. Blum S; Gillis D; Brown H; Boyle R; Henderson R; Heyworth-Smith D; Hogan P; Kubler P; Lander C; Limberg N; Pillans P; Prain K; Staples C; Walsh M; McCombe P; Wong R J Neurol Neurosurg Psychiatry; 2011 Jun; 82(6):659-63. PubMed ID: 21071753 [TBL] [Abstract][Full Text] [Related]
20. Rituximab treatment of myasthenia gravis: A systematic review. Tandan R; Hehir MK; Waheed W; Howard DB Muscle Nerve; 2017 Aug; 56(2):185-196. PubMed ID: 28164324 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]